Nektar(US:NKTR) TMX Newsfile·2026-03-21 12:34Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Nektar Therapeutics, Inc. due to allegations of violations of federal securities laws related to misleading statements and trial results [2][5]. Group 1: Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Nektar to contact them for discussing legal options [1]. - The firm has set a deadline of May 5, 2026, for investors to seek the role of lead plaintiff in a federal securities class action against Nektar [2]. - The complaint alleges that Nektar and its executives made false statements regarding the REZOLVE-AA trial, which could significantly impact the trial's results and integrity [5]. Group 2: Trial Results and Stock Impact - On December 16, 2025, Nektar announced that the Phase 2b REZOLVE-AA trial failed to reach statistical significance, attributing this to the inclusion of ineligible patients [6]. - Following the announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [7].